HYPERTONIA ÉS NEPHROLOGIA - eLitMed.hu

2002; 6 (1):39–49. INDAPAMID VÉRNYOMÁSCSÖKKENTÕ HATÁSA... 49
IRODALOM
1. Joint National Committee on Detection, Evaluation, and Treatment
of High Blood Pressure. The Sixth Report of the Joint
National Committee on Prevention, Detection, and Treatment of
High Blood Pressure (JNC VI). Arch Intern Med 1997; 157:
2413-2446.
2. 1999 World Health Organization - International Society of
Hypertension Guidelines for the Management of Hypertension.
Hypertension 1999; 17:151-183.
3. A hypertonia ellátásának szakmai és szervezeti irányelvei. A Magyar
Hypertonia Társaság állásfoglalása és ajánlása a Belgyógyászati
Szakmai Kollégium jóváhagyásával. Hypertonia és
Nephrologia 2001; 5 (S1):1-44.
4. Hansson L, Lindholm LH, Ekbom T, et al. Randomised trial of
old and new antihypertensive drugs in elderly patients: cardiovascular
mortality and morbidity the Swedish Trial in Old Patients
with Hypertension-2 study. Lancet 1999; 354:1751- 1756.
5. MacMahon S, Rodgers A. Blood pressure, antihypertensive treatment
and stroke risk. J Hypertens 1994; 12 (Suppl. 10):S5-S14.
6. Rodgers A, MacMahon S, Gamble G, et al for the United
Kingdom Transient Ischaemic Attack Collaborative Group:
Blood pressure and risk of stroke in patients with cerebrovascular
disease. Brit Med J 1996; 313:147.
7. Bataillard A, Schiavi P, Sassard J. Pharmacological properties of
indapamide. Rational use in hypertension. Clin Pharmacokinet
1999; 37 (Suppl.1): 7-12.
8. Asmar R, Amah G, Crisan O, Haddad S. Efficacy and tolerance
of indapamide sustained release 1.5 mg on 24-h blood pressure in
essential hypertension. Eur. Heart J. 1999; 1 (Suppl.P):P21-P30.
9. Ambrosioni E, Safar M, Degaute J-P, et al. Low-dose antihypertensive
therapy with 1.5 mg sustained release indapamide:
results of randomised double-blind controlled studies. J
Hypertens 1998; 16:1677-1684.
10. Mallion J-M, Asmar R, Boutelant S, Guez D. Twenty-four hour
antihypertensive efficacy of indapamide, 1.5-mg sustained release:
results of two randomized double-blind controlled studies.
J Cardiovasc Pharmacol 1998; 32: 673-678.
11. Donelly R. Clinical implications of indapamide sustained release
1.5 mg in hypertension. Clin Pharmacokinet 1999; 37(Suppl.1):
21-32.
12. Farsang Cs. Egy új típusú diureticum, az indapamid helye az antihypertensiv
therapiában. Hypertonia és Nephrologia 2000;
4:63-70.
13. McClellan KJ, Markham A. Perindopril 2 mg/indapamide 0.625
mg. Fixed low dose combination. Drugs 1999; 58:297-302.
14. Farsang C. on behalf of the ECHP team. Effective Control of
Hypertension Project of the Hungarian Society of Hypertension.
Eur Soc Hypertension 10 th Meeting, Göteborg, 2000.
15. Garfield FB, Caro JJ. Compliance and hypertension. Curr
Hypertens Reports 1999; 1:502-506.
16. Statson W.B. Compliance, quality of life, and cost effectiveness.
Curr.Hypertens.Reports 1999; 1:471-474.
17. Jones JK., Gorkin L, Lian JF, et al. Discontinuation of and
changes in treatment after start of new courses of antihypertensive
drugs: a study of a United Kingdom population. Brit Med
J 1995; 311:293-295.
18. Greenberg G, Brennan PJ, Miall WE. Effects of diuretic and
beta-blocker therapy in the Medical Research Council Trial. Am
J Med 1984; 76:45-51.